ACETYLSALICYLIC ACID RESISTANCE: RISK FACTORS, MECHANISMS, DIAGNOSTIC TESTS
Open Access
- 1 January 2020
- journal article
- review article
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 6 (2) , 16-34
Abstract
Acetylsalicylic acid (aspirin) is one the most widespread drugs in the world. It is used for secondary prevention of atherothrombotic events in patients with cardiovascular disease. Accordingly, the problem of the effectiveness of aspirin treatment is among the crucial issues of cardiology. The issue of personalization of antiplatelet therapy remains relevant, since there is no convincing evidence in favor of using aspirin for primary prevention in the general population. In this review, recent data on aspirin resistance are considered. Potential mechanisms of non-responsiveness to aspirin, the role of genetic factors, standardization of tests and diagnostic criteria for aspirin resistance, and the treatment options are discussed. The data on the clinical and prognostic value of 11-dehydrothromboxane B2 as a promising marker of thromboxane-dependent platelet activation are analyzed.Keywords
This publication has 91 references indexed in Scilit:
- The Association of Four Common Polymorphisms from Four Candidate Genes (COX-1, COX-2, ITGA2B, ITGA2) with Aspirin Insensitivity: A Meta-AnalysisPLOS ONE, 2013
- Platelet activation and inhibition in polycythemia vera and essential thrombocythemiaBlood, 2013
- Genotype-independent in vivo oxidative stress following a methionine loading test: Maximal platelet activation in subjects with early-onset thrombosisThrombosis Research, 2011
- Platelets, inflammation and tissue regenerationThrombosis and Haemostasis, 2011
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Pharmacogenetics of aspirin resistance: a comprehensive systematic reviewBritish Journal of Clinical Pharmacology, 2008
- Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke ProphylaxisThe Journal of Clinical Pharmacology, 2008
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995